SCHEMBL14367753

SCHEMBL14367753

COC(=O)c1cccc2oc(-c3cccc4oc(-c5ccccc5OC)nc34)nc12

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP2A P11388 3/20 0.77
HTR3A P46098 2/20 0.58
KCNH2 Q12809 2/20 0.58
CYP3A4 P08684 1/20 0.57
VDR P11473 3/20 0.56
MAPT P10636 4/20 0.48
TP53 P04637 2/20 0.48
ESR1 P03372 1/20 0.48
THRA P10827 1/20 0.48
THRB P10828 1/20 0.48
RXRA P19793 1/20 0.48
PPARG P37231 1/20 0.48
PPARD Q03181 1/20 0.48
PPARA Q07869 1/20 0.48
ESR2 Q92731 1/20 0.48
IKBKB O14920 1/20 0.47
ATM Q13315 1/20 0.45
ALDH1A1 P00352 2/20 0.44
PSEN1 P49768 1/20 0.43
PSEN2 P49810 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2959889 0.88 TOP2A (0.61) TOP2AHTR3AKCNH2CYP3A4VDR
SCHEMBL11979724 0.87 TOP2A (1.00) TOP2AHTR3AKCNH2CYP3A4VDR
SCHEMBL17929359 0.87 TOP2A (0.78) TOP2AHTR3AKCNH2CYP3A4VDR
SCHEMBL29354263 0.87 TOP2A (1.00) TOP2AHTR3AKCNH2CYP3A4VDR
SCHEMBL17929348 0.87 TOP2A (1.00) TOP2AHTR3AKCNH2CYP3A4VDR
SCHEMBL17931469 0.86 TOP2A (0.77) TOP2AHTR3AKCNH2CYP3A4VDR
SCHEMBL17929349 0.86 TOP2A (0.77) TOP2AHTR3AKCNH2CYP3A4VDR
SCHEMBL17929362 0.86 TOP2A (0.77) TOP2AHTR3AKCNH2CYP3A4VDR
SCHEMBL17929363 0.85 TOP2A (0.76) TOP2AHTR3AKCNH2CYP3A4VDR
SCHEMBL5619653 0.84 TOP2A (0.95) TOP2AHTR3AKCNH2CYP3A4VDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160207909-A1 Synthesis Method of Anti-Cancer Drug UK-1 and Derivatives Thereof HUANG YUNG-TZUNG (TW) 2016-07-21 US disclosed
US-7294643-B2 UK-1 analogues: methods of preparation and use BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2007-11-13 US disclosed
US-7294643-B2 UK-1 analogues: methods of preparation and use BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2007-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160207909-A1 Synthesis Method of Anti-Cancer Drug UK-1 and Derivatives Thereof ALDH7A1, ADH1A, ALDH1A1 TOP2A 300/4885HTR3A 377/4885KCNH2 4016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.